mesothelioma
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Anna K. Nowak Professor of Medical Oncology and Dean of Medicine, University of Western Australia · University of Western Australia Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma. | Mesothelioma | none | immunotherapy, australia | ||
Dean A. Fennell Professor of Thoracic Medical Oncology, University of Leicester · Leicester Cancer Research Centre / University Hospitals of Leicester Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not. | Mesothelioma | none | immunotherapy, surgery, uk | ||
Hedy L. Kindler Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago · University of Chicago Medicine Comprehensive Cancer Center Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease. | Pancreatic ductal adenocarcinoma, Mesothelioma | none | pancreatic, guidelines | ||
Paul Baas Thoracic Oncologist, Netherlands Cancer Institute; Professor, University of Amsterdam · Netherlands Cancer Institute (NKI-AvL) Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years. | Mesothelioma | none | immunotherapy | ||
Quincy Chu Medical oncologist, Cross Cancer Institute and University of Alberta, Edmonton · Cancer Care Alberta (Alberta Health Services) Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma. | Pleural mesothelioma | none | immunotherapy, trialist |